Folate supplementation reduces the risk of neural tube defect (NTD) pregnancy, and folinic acid has been used to correct cerebral folate deficiency (CFD) in children with developmental disorders. In the absence of systemic folate deficiency, the discovery of autoantibodies (AuAbs) to folate receptor α (FR α ) that block the uptake of folate offers one mechanism to explain the response to folate in these disorders. The association of FR α AuAbs with pregnancy-related complications, CFD syndrome, and autism spectrum disorders and response to folate therapy is highly suggestive of the involvement of these AuAbs in the disruption of brain development and function via folate pathways. The two types of antibodies identified in the serum of patients are blocking antibody and binding antibody. The two antibo dies can be measured by the specific assays described and exert their pathological effects either by functional blocking of folate transport as previously shown or hypothetically by disrupting the FR by an antigen-antibody-mediated inflammatory response. We have identified both IgG and IgM AuAbs in these conditions. The predominant antibodies in women with NTD pregnancy belong to the IgG1 and IgG2 isotype and in CFD children, the IgG1 and IgG4 isotype. This review describes the methods used to measure these AuAbs, their binding characteristics, affinity, cross-reactivity, and potential mechanisms by which folate therapy could work. Because these AuAbs are associated with various pathologies during fetal and neonatal development, early detection and intervention could prevent or reverse the consequences of exposure to these AuAbs.
Introduction
Folate, in its various reduced forms, participates in numerous single-carbon exchange reactions that are essential for purine/DNA/pyrimidine synthesis and amino acid metabolism [ 1 ] . The absorption of folate in the gut is primarily mediated by a proton-coupled folate transporter in the upper ileum [ 2 ] , and the cellular uptake of folate is mediated by folate receptor α (FR α ) [ 3 ] . This receptor is highly expressed in reproductive tissues and plays the all-important role of providing folate to the embryo during the critical stages of development [ 4 ] . Folate deficiency in the mother can lead to pregnancy-related complications including neural tube defects (NTDs) in the fetus. Numerous studies have now established the benefits of folate supplementation in reducing the incidence of NTD pregnancy [ 5 -7 ] . The benefits of folate supplementation in the absence of systemic folate deficiency or genetic abnormalities of folate pathways have not been adequately explained. The identification of FR autoantibodies (AuAbs) in women with a history of NTD pregnancy provides a mechanism by which the developing embryo could be deprived of folate [ 8 ] . Although the cause of this autoimmune disorder in mothers remains unknown, the AuAb directed against the FR α could disrupt folate transport to the fetus. This first report has been confirmed by two independent studies [ 9 , 10 ] . However, our own larger study in an Irish population failed to establish a statistically significant correlation of NTD pregnancy with the presence of FR α antibodies [ 11 ] . Nevertheless, the prevalence of the FR α AuAb and NTD pregnancy in Ireland remains higher than in the rest of Europe and the USA. These FR α AuAbs are also associated with numerous developmental disorders in children such as cerebral folate deficiency (CFD) syndrome [ 12 ] , Rett syndrome [ 13 ] , low functioning autism with neurological deficits [ 14 ] , and autism spectrum disorders (ASD) [ 15 , 16 ] . The AuAbs could exert their effect either by blocking folate transport or potentially by an antibody-mediated immune reaction. In the absence of gross fetal abnormalities, exposure to these AuAbs during fetal development or in early infancy could disrupt the structural refinement of the brain and cause functional deficits in later life. These observations further attest to the importance of folate status during early brain development and to the identification of factors that could disrupt this essential need. Early detection and prompt treatment to correct the deficits could prevent or reverse the neurodevelopmental disorders due to FR α autoimmunity and folate deficiency.
Discovery of FR α AuAbs
Folate deficiency in humans leads to hyperhomocysteinemia and megaloblastic anemia [ 1 ] . The rapid onset of the deficiency and the severity of the hematological abnormality present clinically as anemia and the condition is promptly diagnosed and treated. In adults, neurological deficits such as that seen in B12 deficiency are normally not associated with acquired folate deficiency other than some reports of neurological deficits and dementia in the elderly population [ 17 , 18 ] . Maternal folate deficiency has been associated with pregnancy-related complications including miscarriages and birth defects [ 19 ] . Chemotherapeutic drugs that interfere with folate metabolism [ 20 ] and many autoimmune disorders [ 21 ] are also implicated in pregnancy-related complications. Reports of the effects of folate deficiency on embryonic development and functional deficits have been gathered primarily from animal models of dietary folate deficiency [ 22 , 23 ] and, more recently, from mouse gene knockout models [ 24 , 25 ] . Antibodies to various tissue proteins can be teratogenic to the developing embryo, as amply demonstrated in rat models [ 26 ] . We hypothesized that perhaps an autoimmune mechanism involving the primary transporter of folate to the fetus could play a role in fetal brain abnormalities, and therefore, a systematic analysis of FR α expression and the effects of an antibody to this protein was investigated in a rat model [ 4 ] . Immunohistochemical localization of FR α in the rat with a polyclonal rabbit antiserum to rat placental FR α demonstrated high expression in reproductive tissues and in the developing embryo. Subsequent studies with pregnant dams showed that the antiserum induced embryonic resorptions at higher doses and malformations or no gross structural defects at lower doses when administered on gestation day 8 [ 4 ] . These effects were preventable with the use of pharmacologic doses of folinic acid, suggesting that the antibodies may be blocking the folate uptake via the FR α , leading to folate deficiency in the embryo and to the ensuing pathology. The rescue with folinic acid, which is transported via the reduced folate carrier (RFC), suggested that the deleterious effects of the antibodies could be prevented by treating with adequate amounts of folinic acid. This suggested that if the AuAbs to the FR in women with NTD pregnancy are contributing to the fetal abnormalities, these could be rescued by folinic acid treatment. Subsequent analysis of human serum samples demonstrated the presence of FR α AuAbs in women with a history of an NTD pregnancy [ 8 ] . The properties of these antibodies were confirmed by the high-affinity binding to FR α ( K a = 10 9 -10 10 L/mol) and by their ability to block folate uptake in FR α -expressing KB cells in culture [ 8 ] .
The observation of severely reduced cerebral spinal fluid (CSF) folate levels in children with the CFD syndrome prompted the analysis of serum from these children for the presence of FR α AuAbs, which were found in 89% of the patients with this disorder. Intervention with pharmacologic doses of folinic acid normalized the CSF folate levels with clinical improvement [ 12 ] . Because a number of the patients with CFD showed symptoms that were similar to those associated with ASD, we evaluated patients with low functioning autism and identified FR α -blocking antibodies in 76% of these patients [ 14 ] . This analysis was subsequently extended to children with ASD. In the American ASD population, more than 75% of the children had FR AuAbs, and there was a significant correlation between those with blocking AuAbs and those with lower CSF folate concentrations [ 15 ] . Treatment with folinic acid over 4 months showed a significant improvement in verbal communication, receptive and expressive language, attention, and stereotypical behavior. An independent study conducted in Belgium provided similar results for the FR α -blocking antibody and, in addition, showed that parental FR α AuAbs were associated with an increased risk for ASD [ 16 ] . This review provides data on the detailed characterization of FR α AuAbs and methods for the measurement of these antibodies in serum to diagnose FR α autoimmune disorders along with a discussion of published reports.
Methods

Identification of AuAb isotypes
Apo-FR α (FR α without bound folate), purified from human milk using a protocol previously described for human placental FR [ 8 , 12 ] , was covalently attached in 96-well maleic anhydride-coated plates (Pierce™). Unreacted sites were blocked with goat serum, and an aliquot of test serum or plasma was added and incubated overnight at 4 ° C. The presence of bound human AuAbs was detected by complexing with a secondary peroxidase-conjugated goat antibody against human IgG or human IgM (Vector Laboratories™), followed by a colorimetric reaction with tetramethylbenzidine. The determination of the IgG isotypes was performed in a similar assay using biotin-conjugated secondary monoclonal antibodies against human IgG1, IgG2, IgG3, or IgG4 (Sigma™). After incubation with an avidin-peroxidase complex (Vector Laboratories™), a colorimetric reaction with tetramethylbenzidine identified an AuAb isotype bound to the FR α .
Immunological cross-reactivity of FR α antigen derived from animal sources FR α from human, bovine, goat, and camel milk was used as the antigen to measure the immunoreactivity of FR antigen with the human AuAb in a functional blocking assay whereby the binding of Ab to FR α prevents the subsequent binding of [ 
Immunoreactivity of AuAb with native and denatured FR α
Purified human milk FR α was denatured using urea and DTT, with a temperature of 50 ° C, followed by alkylation with n -ethylmaleimide to prevent refolding. Urea and DTT were removed by dialysis, and the denaturation of FR α was confirmed by a complete loss of [ 3 H] folic acid binding to the protein. The denatured FR α was then tested for immunoreactivity against the native receptor in the blocking FR α AuAb assay ( vide infra ). Immunological cross-reactivity was also tested in an ELISA-based assay for binding AuAbs. Acid/charcoal-treated serum samples ( vide infra ) to remove endogenous folate were incubated with 100-fold excess native FR α or with FR α denatured overnight at 4 ° C and added to maleic anhydride-coated ELISA plates containing covalently bound native FR α .
The same serum samples without preincubation with excess native, or denatured FR α were used as positive controls, and AuAb-negative serum samples were used to correct for any non-specific reactivity in the assay.
Determination of optimum binding of AuAb to FR α and affinity constant
Acid/charcoal-treated serum from subjects positive for blocking AuAb were incubated with 0.3 pmol of purified apo-FR α from human milk. At various periods (1 -24 h), an aliquot was removed and tested for the quantity of the remaining apo-FR α by incubating it with [ For the determination of the affinity of the AuAb, increasing amounts of apo-FR α purified from human milk were incubated overnight at 4 ° C with a constant amount of serum containing AuAbs. [ 3 H] Folic acid was added, and the bound folate was subtracted from the total folate binding capacity of the receptor to determine the quantity of receptors blocked (in picomoles) by the antibody. The ratio of the blocked receptor to the free apo-receptor (B/F) was used for the Scatchard analysis of the binding data.
Displacement of bound AuAbs from FR by folate
To determine the form and concentration of folate needed to displace the bound AuAb from FR α , varying concentrations of folic acid or 5-methyl folate (20 -800 nM) were used to determine the concentration required to displace the FR α -bound AuAb. Acid/charcoal-treated serum samples containing blocking IgG AuAb were added to a maleic anhydride ELISA plate with covalently attached FR α . After overnight incubation at 4 ° C, various concentrations of either folic acid or 5-methyl folate were added to the wells, and the reference (control) wells contained no added folate. After incubation for 2 h at 25 ° C, the wells were washed, and the quantity of the blocking IgG AuAb remaining bound to the FR α in each well was determined by incubating with a second peroxidase-conjugated antihuman IgG antibody for 1 h at 25 ° C and a colorimetric reaction with tetramethylbenzidine. Any reduction in IgG bound, compared with the reference wells lacking added folate, represented the displacement of bound AuAb by the specific folate form used.
Current methodology of binding and blocking AuAb assays
Although the initial identification of the FR α AuAbs was done by isolating IgG in the patient ' s serum that bound [ 3 H] folic acid-labeled FR α , technical refinements were deemed necessary to analyze larger number of samples, and therefore, a functional blocking assay was developed that specifically identifies antibodies that, by virtue of their binding location, prevent the binding of folate and therefore prevent the transport of folate via the FR α . A second assay developed for the detection of binding antibodies utilized an ELISA format whereby apo-FR α immobilized in an ELISA plate assay would capture any IgG that would bind to the protein and could be quantitatively identified using a peroxidase enzyme-linked second antibody and a colorimetric substrate.
Assay for blocking AuAbs to FR α
The testing for blocking AuAbs against FR α was performed by measuring the blocking of radiolabeled folic acid binding to a known amount of purified FR α from human milk as previously described [ 8 ] . Briefly, 200 μ L of serum was acidified with 300 μ L of 0.1 M glycine/HCl, pH 2.5/0.5% Triton X-100/10 mM EDTA and was added to 12.5 mg of dextran-coated charcoal pellet to remove the free folate in the sample. After centrifugation, the supernatant was collected and the pH was neutralized with 40 μ L of 1 M dibasic sodium phosphate. This sample was incubated overnight at 4 ° C with 0.34 pmol of apo-FR α purified from human milk. [ 3 H] Folic acid was added, and the mixture was incubated for 20 min at room temperature. Free [ 3 H] folic acid is then adsorbed to dextran-coated charcoal (5% activated charcoal, 1% dextran in 0.1 M sodium phosphate buffer, pH 7.4), and the receptor-bound radioactivity in the supernatant fraction was determined. Blocking AuAbs prevent the binding of [ 3 H] folic acid to FR α , and the AuAb titer is expressed as picomoles of FR α blocked per milliliter of serum. The blocking Ab could be either IgG or IgM, and this method does not identify any specific antibody type.
Assay for binding AuAbs to FR α
An ELISA-based measurement was used to determine the presence of IgG immunoglobulins that bind to epitopes on purified apo-FR α . In this assay, apo-FR α purified from human milk was immobilized in 96-well maleic anhydride plates (Pierce). Unreacted sites were blocked with goat serum. Aliquots of plasma or serum were added and incubated overnight at 4 ° C. The presence of AuAbs was detected by complexing with a second peroxidaseconjugated goat antibody against human IgG, followed by a colorimetric reaction with tetramethylbenzidine. The AuAb titer (IgG) was quantified from a standard curve using known amounts of human IgG captured in a protein A-coated ELISA plate and color development as described above. Non-specific binding was determined using negative control serum samples. Data are presented as ' binding AuAbs ' and expressed as picomoles of FR α binding IgG per milliliter of serum.
Results and discussion
Properties of FR α AuAbs
Stability of AuAbs upon storage
The first study identifying FR α AuAbs was done with fresh serum samples [ 8 ] . However, subsequent studies in both NTD pregnancy and CFD syndromes were done with serum samples kept frozen for various periods. Because the stability of proteins in a biological sample is a valid concern, we performed both blocking and binding assays on samples stored under two different conditions. Serum samples containing varying titers of AuAbs to FR α were aliquoted and stored at either 4 ° C or − 20 ° C. At various time intervals (1, 85, 155, 266, 337 , and 407 days), an aliquot was assayed for blocking and binding AuAb to FR α ( Figure 1 ) . About half the samples stored at 4 ° C showed some decrease in blocking Ab titer over time. However, the decrease amounted to < 45% of the initial mean value after more that 10 months. This decrease was much less for samples stored at − 20 ° C, in that only 30% of the samples showed a decrease in blocking, with the decrease amounting to < 25% of the initial mean value. A similar analysis of binding Ab showed a decrease in titer in 42% of the samples, with the mean decrease amounting to 33% of the initial value in samples stored at 4 ° C. As with the blocking Ab, the binding Ab was more stable when stored at − 20 ° C, with only 8% of the samples showing any decrease in titer. This decrease amounted to 24% of the initial mean value. In no case did the Ab titer change from positive to negative. From these data, it was clear that the FR α antibody in serum was relatively stable under long-term storage conditions and could be used for future studies.
Specific AuAb types in FR autoimmune disorders
The initial trigger for FR α AuAb production in these disorders is not known, and therefore, to better understand the immune response, the specific type of immunoglobulin produced was identified using isotype-specific monoclonal antibodies. As shown in Table 1 , all subjects with this autoimmune condition had IgG antibodies, with IgG1 as the predominant isotype. Mothers with NTD pregnancy (40%) and ASD subjects (14%) also contained IgG2; CFD (21%) and ASD (7%) subjects also had IgG3 isotype. Although the occurrence of IgG4 is rare, 79% of the CFD subjects and 14% of the ASD subjects had this isotype. The conversion to IgG4 is believed to occur as a result of repeated and frequent exposure to an antigen. A number of patients (26% -28%) also had IgM antibodies with blocking activity, and it is likely to be the only antibody type in patients who are negative for binding Ab because binding Ab assay only detects IgG. In CFD subjects, one factor contributing to the increase in antibody titer is the daily consumption of animal milk, which contains substantial amounts of FR α ( Figure 2 Α ) . Bovine milk contains 1 -3 μ g/mL FR α , and a compromised immune barrier in the gut either due to infection and/or inflammation appears to present the antigen to the immune system to mount a response. The substantial similarity in the primary structure of FR α from animal origin with that of human FR α provides the epitopes for molecular mimicry to produce antibodies that cross-react. This is evident from the cross-reactivity of FR AuAbs with milk-derived FR α of animal origin ( Figure  2 B ). This hypothesis is further supported by the dramatic decrease in antibody titer in CFD patients maintained on a dairy-free diet [ 27 ] . However, patients with ASD who have been kept off milk for various reasons still show antibody titers that are considered elevated. Non-compliance to a strict dairy-free diet may partially contribute to the persistent Ab titer in ASD. Camel milk has been touted as beneficial in ASD. Unfortunately, the FR α from camel milk is highly reactive with the AuAb ( Figure 2 B) and is likely to increase the antibody titer, as we have observed in cases when camel milk was introduced (unpublished data).
Binding characteristics of the AuAbs
In developing assays for the detection of blocking and binding antibodies, the time of incubation for optimum binding has to be considered. As shown in Figure 3 A, optimum binding required overnight incubation at 4 ° C, and the long incubation time required may be a function of the antibody and antigen concentration in the incubation reaction. However, the binding is a high-affinity interaction in the nanomolar range, as shown in Figure  3 B. This is consistent with the affinity constants of 10 9 -10 10 L/mol that we have previously reported [ 8 , 12 ] . Another property of the antibodies relevant to the assay development was the inability of the antibodies to react with denatured and linearized polypeptide of FR in the ELISA assay, which supports the notion that the AuAbs are conformation specific and can bind to the native protein with or without the folate attached ( Figure 4 A) . Similarly, the denatured FR α protein does not react in the blocking assay, indicating the need for a fully functional native protein in this assay as well ( Figure 4 B) . Therefore, synthetic peptides or truncated protein fragments are unlikely to be suitable antigens in future assay developments for FR α AuAbs.
In addition to decreasing the antibody titer, the treatment of choice in these autoimmune disorders has been to administer daily pharmacologic doses of folinic acid or methylfolate orally to restore the CSF folate and correct the CFD. These two reduced forms of folates can be transported by alternate routes such as the high-capacity/ low-affinity RFC, which can transport these folates when the local concentration is increased. An empirical dose of 0.5 -2 mg of folinic acid or 0.1 -0.25 mg of methylfolate per kilogram of body weight for the two reduced form of folates has been reached by trial and error. The advantage of administering 5-methylfolate is that, in addition to being transported via the RFC, a high local concentration of methylfolate, which also binds to the FR α with relatively high affinity, could effectively dissociate the AuAb from the FR α and prevent AuAb from binding to the FR α while it is transporting the methylfolate via this receptor. However, this form of folate has to be processed via the methionine synthase pathway for folate-dependent reactions. The advantage of using folinic acid is that it is an approved drug tested for use at high doses in other conditions and is readily available for folate-dependent reactions. Because a fraction of the folinic acid can be converted to methylfolate during absorption in the gut, it can increase the local concentration of folinic acid as well as methylfolate. The ability of methylfolate to displace the bound antibody from FR α , tested using Ab-positive serums, showed that 50 nM 5-methylfolate was able to displace more than 80% of the bound Ab ( a high affinity for FR α ( Figure 5 B) . As previously reported [ 3 ] , folinic acid binds weakly to FR α and therefore cannot displace the antibody. Based on the K t of approximately 5 nM for transport of methylfolate via the FR α [ 28 ] and a concentration of 50 nM required to displace the AuAb, an oral dose sufficient to increase the folate concentration in the circulation to 50 -100 nM would be sufficient to normalize the CSF folate status. Because of the K t of approximately 5 μ M for folinic acid transport via the RFC [ 29 ] , the folinic acid dose would have to be considerably higher to increase the concentration of this folate to the 10-to 50-μ M range. The conversion of a fraction of this during intestinal absorption would also provide some methylfolate to displace the AuAb and be transported via the FR α . Using the current assays described in the Methods section, we have analyzed serum samples from disorders linked to pregnancy and fetal abnormalities to neurodevelopmental disorders in children, and the results are summarized in Table 2 .
The significant association of FR α AuAbs with NTD pregnancy has been confirmed by three independent studies [ 8 -10 ] . The lack of a significant association of FR α antibodies with NTD pregnancy in the Irish population [ 11 ] , despite the higher prevalence of the antibody and the higher incidence of NTD pregnancy than in the US population, points to other compounding factors. What additional genetic and epigenetic factors contribute to the NTD outcome in different populations? Whether FR α AuAbs contribute to the pathology in the Irish population is yet to be determined. However, the association of FR α AuAbs with neurodevelopmental disorders including CFD syndromes and ASD is very strong, and treatments to reduce the antibody titer and inflammation along with pharmacologic doses of folinic acid to restore the CSF and cerebral folate levels have been extremely beneficial in correcting and preventing neurological deficits.
As we age, the immune system also changes, leading to immunosenescence, and therefore, AuAbs to many antigens are prevalent in the elderly population [ 30 , 31 ] . This trend is also seen for blocking FR α AuAbs, whose prevalence increases from < 2% in those younger-than-16-years age group to approximately 10% in the 18-to-35-years age group, and with approximately 25% of the older-than-65-years age group testing positive for the antibody ( Figure 6 ). The significance of the increase in antibody titer in the elderly population, and if this contributes to CFD and dementia or decrease in brain function and if this population would benefit from folate supplementation, needs to be evaluated.
Utility of FR AuAb testing
The identification of FR AuAbs and its association with pregnancy-related complications as well as neuro- developmental disorders adds a whole new dimension to evaluating and treating folate deficiency-related disorders.
It highlights the role of folate in embryonic and neural development. The association of FR α AuAbs in a majority of ASD children and one or both parents and significant improvement in the core clinical symptoms of ASD with folinic acid therapy further highlights the role of folate in structural and functional integration of the developing brain. Even though we do not understand the molecular basis for the FR autoimmune disorder, identifying women and children at risk could be accomplished by a simple blood test. Considering the risk to fetal as well as neonatal brain development, early detection and intervention is likely to yield the best outcome. Population studies involving children, women, and men of all ages should be initiated to evaluate the prevalence, association, and risk of FR α AuAbs. 
